Laurus Labs Limited (NSE: LAURUSLABS)
India
· Delayed Price · Currency is INR | Market Cap | 301.50B |
| Revenue (ttm) | 50.53B |
| Net Income (ttm) | 1.31B |
| Shares Out | 539.16M |
| EPS (ttm) | 2.42 |
| PE Ratio | 230.65 |
| Forward PE | 65.74 |
| Dividend | 0.80 (0.14%) |
| Ex-Dividend Date | Nov 6, 2024 |
| Volume | 1,285,224 |
| Open | 572.80 |
| Previous Close | 572.55 |
| Day's Range | 556.30 - 575.00 |
| 52-Week Range | 360.85 - 593.00 |
| Beta | 1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 24, 2025 |
About Laurus Labs
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser... [Read more]
Financial Performance
In 2023, Laurus Labs's revenue was 50.41 billion, a decrease of -16.55% compared to the previous year's 60.41 billion. Earnings were 1.61 billion, a decrease of -79.68%.
Financial StatementsNews
Mixed trends in November CDRMO exports, prefer Syngene and Neuland Labs over Divis Labs and Laurus Labs
Goldman Sachs notes mixed trends in November for Indian contract development and manufacturing organizations (CDMOs). Monthly export figures showed variability, with Neuland Labs recording a sharp 276...
Laurus Bio secures 120 cr investment
Laurus Bio, a subsidiary of Laurus Labs, has received an equity investment of ₹120 crore from Eight Roads Ventures and F-Prime Capital, aimed at enhancing its fermentation-based manufacturing capabili...
T’gana pharma biggies to inject 5,200cr in Pharma City, create over 12,000 jobs
Top pharmaceutical companies in Telangana, including Laurus Labs and Gland Pharma, are set to invest ₹5,260 crore in the Pharma City project, aiming to create over 12,000 jobs while focusing on green ...
Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade
Time Stamp: November 4, 2024, 9:41 AM Market Update: Pharma stocks opened with a mixed trend today, showing slight gains and losses among the major players. SPARC: Down by 1.81%, trading at ₹212.04 PP...
Laurus Labs Ltd (BOM:540222) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...
Laurus Labs Ltd (BOM:540222) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
Laurus Labs Q2 FY25 Results: Revenue flat, net profit declines 55% YoY
Laurus Labs has reported its Q2 FY25 financial results, showing a flat revenue performance while net profit dropped significantly year-on-year (YoY). Key Financial Highlights (YoY): Revenue: Q2 FY25: ...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Laurus Labs passes US FDA inspection for API manufacturing facility in Hyderabad
Laurus Labs Ltd has recently informed exchanges that the company successfully completed the US Food and Drug Administration (US FDA) audit of its API manufacturing plant in Hyderabad. The audit result...
Laurus Labs share jumps 5% after US House passes Biosecure Act
Laurus Labs’ stock rose more than 5% in early trading after the US House of Representatives passed the Biosecure Act, which aims to strengthen the pharmaceutical supply chain and promote domestic dome...